Drugs / IL13Ra2-specific CAR Tn/mem cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02208362 | May 2015 → Feb 2021 overdue | glioblastoma, grade II glioma, grade III glioma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL13Ra2-specific CAR Tn/mem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02208362 ↗ |
| Action | Deplete | “a modified gene is placed into them in the laboratory and this may help them recognize and kill glioma cells.” NCT02208362 ↗ |
| Modality | Cell therapy | “CAR-T therapy is an emerging strategy” PMID 38454126 ↗ Mar 2024 |
| Route | Other | “directly into the tumor (intratumoral)” NCT02208362 ↗ |
| Target | IL13RA2 | “CAR-engineered T cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13Rα2).” PMID 28029927 ↗ Dec 2016 |